Skip to content

The sevoflurane concentration for light sedation in critically ill patients: an experimental study

The sevoflurane concentration for light sedation in critically ill patients: an experimental study

Status
Unknown
Phases
Phase 4
Study type
Interventional
Source
TCTR
Registry ID
TCTR20230825001
Enrollment
20
Registered
2023-08-25
Start date
2023-09-11
Completion date
Unknown
Last updated
2026-03-30

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Sedation level Sevoflurane, conscious sedation, Intensive Care Units

Interventions

Before starting sedation, all patients were pain control patients with a target behavioral pain scale of less than 6 or a numeric rating scale of less than 3. Sevoflurane was titrated via Anaconda-S t
s method, end tidal sevoflurane concentration will be increased or decreased by 0.1 in the following patient depending on the previous patient&#039
s response. The maximum end-tidal sevoflurane concentration target is 1.4, according to the manufacturer&#039
s recommendations. During sedation, if patients&#039
hypotension is defined as mean arterial pressure (MAP) below 65 mmHg will start vasopressor or inotropic agents are to keep MAP of more than 65 mmHg.
Experimental Drug

Sponsors

Ramathibodi Hospital
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 99 Years

Inclusion criteria

Inclusion criteria: Adult patients age more than and equal to 18 years old. RASS > 1 and need sedation. Patient on a mechanical ventilator for at least 12 hours in medical or surgical intensive care units

Exclusion criteria

Exclusion criteria: Patients who have a history or family history of malignant hyperthermia. Patients who have evidence of raised intracranial pressure. Patients with low tidal volumes (<200 ml) and one-lung ventilation.patients who have persistent bronchopleural fistula despite chest tube drainage. Patients with epidural or regional analgesia Patients who receive vasopressor > 0.1 mcg/kg/min of norepinephrine-equivalent dose. Patients who lack of commitment to ongoing critical care treatment. Patients whose medication uses a nebulizer. Patients cannot inform consent. Pregnancy Patients with pulmonary disease who have a PF ratio<200. Patients who have APACHE scores> 20.

Design outcomes

Primary

MeasureTime frame
ED 50 ED95 30 minutes RASS

Secondary

MeasureTime frame
Length of intensive care unit stay within 1 year Days,Duration of ventilator day 28 days Days,Incidence of delirium 28 days Percents,Hemodynamic variables 30 minutes Numeric ,Respiratory variables 30 minutres Numeric

Countries

Thailand

Contacts

Public ContactChawika Pisitsak

Ramathibodi Hospital

chawika_p@hotmail.com022011552

Outcome results

None listed

Source: TCTR (via WHO ICTRP) · Data processed: Apr 4, 2026